ImmuPharma chair hails “successful” recruitment for Lupuzor™ trials

Tim McCarthy, ImmuPharma’s Chairman speaks to Proactive Investor following today’s Preliminary Results  announcement, giving progress on Lupuzor’s™ Phase III pivotal trial and the forthcoming Symposium on 8/9 June where the inventor of Lupuzor™, Prof. Sylivane Muller will be in London presenting on Lupuzor’s™ unique mechanism of action and why it is so effective in treating Lupus patients, based on Phase IIb trials.